Amphastar Pharmaceuticals develops, manufactures, and markets specialty injectable and inhalation pharmaceutical products. Its portfolio spans generic and proprietary formulations used in hospitals and other care settings, including complex dosage forms that require specialized manufacturing. The company focuses on products where technical barriers and supply reliability matter as much as the active ingredient itself.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 174.4 | — | 31 | — |
| Q3 2025 | 191.8 | — | 17.4 | — |
| Q4 2025 | 183.1 | — | 24.4 | — |
| Q1 2026 | 171.2 | — | 6.4 | — |
| Q2 2026 | 183.9 | 5.4% | 30.4 | -2.2% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Willdan Group, Inc. (WLDN), Hotel101 Global Holdings Corp. (HBNB), Tripadvisor, Inc. (TRIP), Frontier Group Holdings, Inc. (ULCC), Nanobiotix S.A. (NBTX), Omada Health, Inc. (OMDA)